Outcomes of COVID-19 among patients with liver disease

World Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 29(5), P. 815 - 824

Published: Feb. 2, 2023

Coronavirus disease 2019 (COVID-19) is primarily a respiratory with multi-organ involvement, including impaired liver function. It has been noticed that significant proportion of COVID-19 patients have dysfunction, especially those more severe course. The coronavirus causes direct damage to the using angiotensin-converting enzyme 2, cell-surface receptor for cellular entry, expressed in liver. According previous research, abnormalities were observed considerable patients, and elevated transaminases found about 20% these alkaline phosphatase 6.1%, gamma-glutamyl transferase 21.1%. might trigger deterioration function pre-existing chronic diseases (CLDs) also without disorders. majority who develop injury are men, elderly, higher body mass index. Compared general population, associated morbidity mortality (cirrhosis transplantation recipients). However, some studies indicate CLDs lesser role determining patient progression towards severity.

Language: Английский

---

COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations

World Journal of Hepatology, Journal Year: 2023, Volume and Issue: 15(4), P. 441 - 459

Published: April 20, 2023

The coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 is an ongoing health concern. In addition to affecting the system, COVID-19 can potentially damage other systems in body, leading extra-pulmonary manifestations. Hepatic manifestations are among common consequences of COVID-19. Although precise mechanism liver injury still questionable, several mechanisms have been hypothesized, including direct viral effect, cytokine storm, hypoxic-ischemic injury, hypoxia-reperfusion ferroptosis, and hepatotoxic medications. Risk factors COVID-19-induced include infection, male gender, advanced age, obesity, underlying diseases. presentations involvement comprise abnormalities enzymes radiologic findings, which be utilized predict prognosis. Increased gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase levels with hypoalbuminemia indicate anticipate need for intensive care units' hospitalization. imaging, a lower liver-to-spleen ratio computed tomography attenuation may more illness. Furthermore, chronic patients at higher risk death from Nonalcoholic fatty had highest death, followed metabolic-associated cirrhosis. pandemic has also altered epidemiology pattern some hepatic diseases, such as alcoholic hepatitis B. Therefore, it warrants special vigilance awareness healthcare professionals screen treat COVID-19-associated accordingly.

Language: Английский

---

Liver Involvement during SARS-CoV-2 Infection Is Associated with a Worse Respiratory Outcome in COVID-19 Patients

Viruses, Journal Year: 2023, Volume and Issue: 15(9), P. 1904 - 1904

Published: Sept. 10, 2023

Coronavirus disease of 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), may be complicated life-threatening interstitial pneumonia. SARS-CoV-2 infection also damage several tissues and/or organs beyond the lungs, including liver. However, controversy still exists as to whether SARS-CoV-2-induced liver alterations can have an impact on outcome COVID-19. The aim this study was therefore assess SARS-CoV-2-infected patients with abnormalities at time hospital referral had a worse respect no biochemistry alterations. To end, medical records 123 admitted our COVID center between end 2020 and spring 2021 were retrospectively reviewed. Patients divided into two groups: those normal biochemistries (group 1, 77 patients) altered function tests 2, 46 patients). Serum levels aminotransferases (AST ALT) bile duct cell injury markers (γ-GT ALP) used dichotomize patients. A higher percentage enzyme found develop COVID-19 pneumonia group 1 (74% vs. 65%); moreover, they needed more days support and, importantly, intensive administration supplemental oxygen. statistically significant correlation aminotransferase duration support. mortality rate not superior in In conclusion, admission predisposed development pneumonia, because longer requirement for oxygen support, indicative evolution these

Language: Английский

---

COVID-19, Possible Hepatic Pathways and Alcohol Abuse—What Do We Know up to 2023?

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2212 - 2212

Published: Feb. 12, 2024

The pandemic period due to coronavirus disease 2019 (COVID-19) revolutionized all possible areas of global health. Significant consequences were also related diverse extrapulmonary manifestations this pathology. liver was found be a relatively common organ, beyond the respiratory tract, affected by severe acute syndrome coronavirus-2 (SARS-CoV-2). Multiple studies revealed essential role chronic (CLD) in general outcome infection. Present concerns field are direct hepatic caused COVID-19 and pre-existing disorders as risk factors for course Which mechanism has key phenomenon—previously existing disorder or failure SARS-CoV-2—is still not fully clarified. Alcoholic (ALD) constitutes another elucidated context Should toxic effects ethanol already developed cirrhosis its perceived causative triggering factor impairment patients? In face these discrepancies, we decided summarize whole picture infection, paying special attention ALD focusing on pathological pathways COVID-19, toxicity cirrhosis.

Language: Английский

---

Impact of nonalcoholic fatty liver disease on clinical outcomes in patients with COVID-19 among persons living with HIV: A multicenter research network study

Journal of Infection and Public Health, Journal Year: 2023, Volume and Issue: 16(5), P. 673 - 679

Published: Feb. 13, 2023

People living with human immunodeficiency virus (PLWH) are at an increased risk of nonalcoholic fatty liver disease (NAFLD) but how these patients react to COVID-19 infection is unclear. We examined the clinical characteristics and outcomes without among people diagnosed COVID-19.

Language: Английский

---

Association between alcohol-associated cirrhosis and inpatient complications among COVID-19 patients: A propensity-matched analysis from the United States

World Journal of Virology, Journal Year: 2023, Volume and Issue: 12(4), P. 221 - 232

Published: Sept. 19, 2023

Alcohol-associated cirrhosis (AC) contributes to significant liver-related mortality in the United States. It is known cause immune dysfunction and coagulation abnormalities. Patients with comorbid conditions like AC are at risk of worse clinical outcomes from coronavirus disease 2019 (COVID-19). The specific association between COVID-19 remains inconclusive, given lack robust evidence prior studies.To study predictors patients hospitalized States.We conducted a retrospective cohort using National Inpatient Sample (NIS) database 2020. were identified primary hospitalizations based on an underlying diagnosis AC. A matched comparison without was after 1:N propensity score matching baseline sociodemographic characteristics Elixhauser comorbidities. Primary included median length stay, inpatient charges, in-hospital mortality. Secondary prevalence systemic complications.A total 1325 1135 There no difference stay hospital charges compared non-AC (P > 0.05). increased septic shock (5.7% vs 4.1%), ventricular fibrillation/ventricular flutter (0.4% 0%), atrial fibrillation (13.2% 8.8%), (8.7% 4.4%), first-degree atrioventricular nodal block (0.8% upper extremity venous thromboembolism (1.5% variceal bleeding (3.8% 0%) < AC, odds ratio 0.97 (95% confidence interval: 0.78-1.22, P = 0.85). Predictors advanced age, cardiac arrhythmias, coagulopathy, protein-calorie malnutrition, fluid electrolyte disorders, shock, thromboembolism.AC does not increase COVID-19. complications among non-AC.

Language: Английский

---

Risk of severe disease and mortality of COVID ‐19 in patients with Budd‐Chiari syndrome: A population‐based matched cohort study

Liver International, Journal Year: 2023, Volume and Issue: 43(5), P. 1141 - 1144

Published: Feb. 24, 2023

Budd-Chiari syndrome (BCS) is a rare and potentially life-threatening disorder characterized by obstruction of the hepatic outflow tract. It unknown whether patients with BCS represent high risk for severe disease mortality from coronavirus 2019 (COVID-19). Thus, we aimed to assess hospitalization rates, disease, all-cause mortality, intensive care unit (ICU) requirement acute kidney injury (AKI) COVID-19 diagnoses.We identified 467 COVID-19, 96 427 non-chronic liver (CLD) 9652 non-BCS CLD. The non-CLD cohorts (n = each) CLD 440 were well balanced after propensity matching. When compared cohort, group had higher (5.1% vs. 2.4%, HR 2.18; 95% CI, 1.08-4.40), (6.0% 2.20; 1.09-4.43), (24.6% 13.1%, 1.77; 1.30-2.42) AKI (7.9% 2.8%, 2.57; 1.37-4.85), but no significant differences in ICU requirements (2.4% 2.1%, 0.75; 0.27-2.08) at 60-days time points. (3.6% 2.5%, 3.94; 1.31-11.79), (29.8% 21.6%, 1.43; 1.09-1.86), (HR 0.90 (0.38-2.12)), 1.41 (0.86-2.30)) or 1.92 (0.99-3.71)) did not reach statistical significance 60-day follow up.In conclusion, infection associated poor outcomes. Patients infected carry significantly possible effect on without non-BCS-CLD.

Language: Английский

---

Aspartate aminotransferase to platelet ratio index has utility as a biomarker of COVID‐19 severity in patients with nonalcoholic fatty liver disease

Hepatology Research, Journal Year: 2023, Volume and Issue: 53(11), P. 1047 - 1058

Published: July 20, 2023

Patients with nonalcoholic fatty liver disease (NAFLD) are reported to have greater coronavirus 2019 (COVID-19) severity compared patients without NAFLD. Previous studies that noninvasive fibrosis scores, including the Fibrosis-4 index, NAFLD score, and aspartate aminotransferase platelet ratio index (APRI), utility in predicting COVID-19 mortality However, of scores among infected SARS-CoV-2 has yet be evaluated.This retrospective observational study comprised 126 active infection. were classified into low (mild or moderate I disease) high (moderate II severe groups based on therapeutic guideline implemented by Ministry Health, Labor, Welfare Japan.Of patients, only one had been diagnosed before admission. Age; levels serum aminotransferase, γ-glutamyl transpeptidase, lactate dehydrogenase, blood urea nitrogen, C-reactive protein; index; score; APRI admission higher group group. Serum albumin levels, counts, lymphocyte counts lower Univariate multivariate analysis revealed values significantly associated hospitalization duration for COVID-19.APRI was independently

Language: Английский

---

Impact of COVID-19 on mortality rate in patients with chronic liver diseases, single-centre observational study

Medical Journal of Viral Hepatitis /Medical Journal of Viral Hepatitis, Journal Year: 2023, Volume and Issue: 7.2(2), P. 15 - 22

Published: April 1, 2023

Background: Coronavirus induced disease-19 (COVID-19), is a serious disease by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).Liver cirrhosis and its complications are currently ninth most common cause of death worldwide.This work aims to evaluate impact COVID-19 on mortality rate in patients with CLD. Patients methods:The current study included 120 who were distributed according state liver affection into two groups; group 1 60 combined CLD free from CLD.All cases reviewed obtain data about general history, clinical examination laboratory investigations rate.Results: Compared without chronic diseases, diseases had significant (60% versus 20% respectively).Among was statistically significantly higher decompensated (100%) followed hepatocellular carcinoma (80%) lowest found (46.7%).Multivariate regression analysis showed that increasing age, decreased albumin concentration, INR PT independent predictors for diseases.Conclusion: worse outcomes compared COVID -19 diseases.Among linked worst outcome. methodsThis prospective observational conducted at Mansoura University Hospital, Mansoura, Egypt.The groups liver, Group (60 CLD) CLD).The diagnosis based symptoms signs (fever, cough, breathing difficulties or organ failures 13 , findings (elevation inflammatory biomarkers as (CRP, ferritin, lactate dehydrogenase, D-dimer INR, decrease lymphocyte count serum K level 14 positive result reverse transcription polymerase chain ________________________

Language: Английский

---